Stage IVB Rectal Cancer Withdrawn Phase 1 / 2 Trials for Infigratinib (DB11886)

IndicationStatusPhase
DBCOND0028589 (Stage IVB Rectal Cancer)Withdrawn1 / 2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT02575508Pan FGFR Kinase Inhibitor BGJ398 and Combination Chemotherapy in Treating Patients With Untreated Metastatic Pancreatic CancerTreatment